{
  "id": 1959274,
  "title": "Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near",
  "url": "https://urgent.news/2026/08/19/amylin-design-debate-heats-up-as-lillys-crucial-mid-stage-weight-loss",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T14:52:57.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/amylin-design-debate-heats-up-as-lillys-crucial-mid-stage-weight-loss-data-near/"
  },
  "original_language": "en",
  "account": null,
  "summary": "In the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agonist to ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}